The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials.

Clinical trial design clinical trial outcome measures functional rating scale harmonization statistical analysis

Journal

Amyotrophic lateral sclerosis & frontotemporal degeneration
ISSN: 2167-9223
Titre abrégé: Amyotroph Lateral Scler Frontotemporal Degener
Pays: England
ID NLM: 101587185

Informations de publication

Date de publication:
23 Feb 2024
Historique:
medline: 24 2 2024
pubmed: 24 2 2024
entrez: 24 2 2024
Statut: aheadofprint

Résumé

The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) was developed more than 25 years ago as an instrument to monitor functional change over time in patients with ALS. It has since been revised and extended to meet the needs of high data quality in ALS trials (ALSFRS-R), however a full re-validation of the scale was not completed. Despite this, the scale has remained a primary outcome measure in clinical trials. We convened a group of clinical trialists to discuss and explore opportunities to improve the scale and propose alternative measures. In this meeting report, we present a call to action on the use of the ALSFRS-Revised scale in clinical trials, focusing on the need for (1) harmonization of the ALSFRS-R administration globally, (2) alignment on a set of recommendations for clinical trial design and statistical analysis plans (SAPs), and (3) use of additional outcome measures.

Identifiants

pubmed: 38396337
doi: 10.1080/21678421.2024.2320880
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-6

Auteurs

Angela Genge (A)

Montreal Neurological Institute-Hospital, ALS Center of Excellence, Montreal, Quebec, Canada.

Jesse M Cedarbaum (JM)

Yale School of Medicine, Section of Movement Disorders, Coeruleus Clinical Sciences LLC, Woodbridge, CT, USA.

Jeremy Shefner (J)

Barrow Neurological Institute, Phoenix, AZ, USA.

Adriano Chio (A)

Department of Neuroscience, University of Turin, Torino, Italy.

Ammar Al-Chalabi (A)

Department of Basic and Clinical Neuroscience, King's College London, Institute of Psychiatry Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.

Philip Van Damme (P)

Department of Neurology, KU Leuven, Leuven, Belgium.

Chris McDermott (C)

Department of Neurology, The University of Sheffield, Sheffield, UK.

Jonathan Glass (J)

Department of Neurology, Emory University, Atlanta, GA, USA.

James Berry (J)

Massachusetts General Hospital, Neurology, Boston, MA, USA.

Ruben P A van Eijk (RPA)

Department of Neurology and Biostatistics, UMC Utrecht Hersencentrum Rudolf Magnus, Utrecht, Netherlands.

Christina Fournier (C)

Department of Neurology, Emory University, Atlanta, GA, USA.

Julian Grosskreutz (J)

Precision Neurology of Neuromuscular and Motoneuron Diseases, University of Lübeck, Lübeck, Germany.

Jinsy Andrews (J)

Columbia Presbyterian Medical Center, Neurology, New York, NY, USA.

Vanessa Bertone (V)

Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada.

Tommy M Bunte (TM)

Department of Neurology, UMC Utrecht Hersencentrum Rudolf Magnus, Utrecht, Netherlands.

Mathias Couillard (M)

Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada.

Cathy Cummings (C)

International Alliance of ALS/MND Associations, Northampton, Northamptonshire, UK, and.

Gale Kittle (G)

Barrow Neurological Institute, Phoenix, AZ, USA.

John Polzer (J)

QurAlis, Cambridge, MA, USA.

Kristiana Salmon (K)

QurAlis, Cambridge, MA, USA.

Corey Straub (C)

QurAlis, Cambridge, MA, USA.

Leonard H van den Berg (LH)

Department of Neurology, UMC Utrecht Hersencentrum Rudolf Magnus, Utrecht, Netherlands.

Classifications MeSH